Vivitrol

E597292

Vivitrol is an extended-release injectable formulation of naltrexone used to treat alcohol and opioid dependence by blocking the effects of these substances.

Try in SPARQL Jump to: Statements Referenced by

Statements (47)

Predicate Object
instanceOf brand name drug
extended-release injectable formulation
medication
activeIngredient naltrexone
administrationBy healthcare professional
ATCCode N07BB04 NERFINISHED
blackBoxWarning risk of hepatotoxicity with naltrexone
vulnerability to opioid overdose after treatment
commonAdverseEffect dizziness
elevated liver enzymes
fatigue
headache
injection site pain
nausea
contraindication acute hepatitis
acute opioid withdrawal
current opioid use
failure to pass naloxone challenge test
liver failure
positive opioid urine screen
dosageForm suspension for injection
dosingInterval once monthly
effect blocks effects of exogenous opioids
reduces rewarding effects of alcohol
eliminationHalfLife approximately 5–10 days (extended-release)
FDAApprovalYear 2006
FDAApprovedFor prevention of relapse to opioid dependence after opioid detoxification
treatment of alcohol dependence
formulationType extended-release
indication alcohol dependence
opioid dependence
prevention of relapse to opioid dependence
legalStatus prescription only
manufacturer Alkermes plc NERFINISHED
mechanismOfAction blocks mu-opioid receptors
opioid receptor antagonist
pregnancyCategoryUS Category C
requires opioid-free period of at least 7–10 days before initiation
routeDetail deep intramuscular injection in the gluteal muscle
routeOfAdministration intramuscular injection
seriousAdverseEffect depression
hepatitis
injection site necrosis
suicidal ideation
strength 380 mg naltrexone base
usedWith counseling
psychosocial support

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Alkermes product Vivitrol